Novavax shares dropped Tuesday morning after the company slashed its full-year outlook when it announced its third-quarter results.
Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious diseases, ...
The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 ...
Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on hold.
The U.S. Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its standalone flu vaccines after a safety concern was found unrelated to the ...
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
Novavax's COVID-19 vaccine continues to be its only commercial product and currently has about 2%-3% market share, ...
We continue to work closely with our partner to enable a seamless ... immunologic comparisons to establish non-inferiority ...
Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall and winter seasons. Here we answer common questions about the latest ...
(MENAFN- Live Mint) (Bloomberg) -- Novavax Inc. shares fell as much as 24% after US regulators placed a hold on the company's experimental influenza and COVID-19 combination vaccines because a ...